Home Ingredients Lactobacillus paracasei (Multi-Strain Specialist)
Immune SupportRespiratory HealthGut Health

Lactobacillus paracasei (Multi-Strain Specialist)

Lacticaseibacillus paracasei (formerly Lactobacillus paracasei) — multiple strains
Evidence Level
Moderate
3 Clinical Trials
6 Documented Benefits
3/5 Evidence Score

A probiotic species (recently reclassified taxonomically as Lacticaseibacillus paracasei) with multiple strain-specific clinical applications — strain selection is essential because different strains have distinct evidence bases. Key strains: L. casei 431® (Chr. Hansen) for respiratory symptoms; KW3110 (Kirin) for pollen allergy; NCC2461 (Nestlé) for allergic rhinitis; GM-080 (Genmont) for pediatric allergic rhinitis; IJH-SONE68 (plant-derived) for chronic allergy. Trilling 2015 (, Am J Clin Nutr) — 1,104-subject 42-day RCT of L. casei 431® reduced upper respiratory symptom duration but had no effect on influenza vaccine antibody titers. Generic 'L. paracasei' supplements should not be assumed equivalent to evidence-based strains.

Studied Dose L. CASEI 431® RESPIRATORY: ≥1×10⁹ CFU/day × 42 days. KW3110 POLLEN ALLERGY: 4×10¹⁰ CFU/day yogurt × 12 weeks. GM-080 PEDIATRIC AR: 2×10⁹ CFU/day × 3 months. IJH-SONE68 CHRONIC ALLERGY: per trial × 12 weeks. Strain selection essential — generic L. paracasei not equivalent.
Active Compound Lacticaseibacillus paracasei (recently reclassified from Lactobacillus paracasei) — multiple specific strains: L. casei 431 (Chr. Hansen), KW3110 (Kirin), NCC2461 (Nestlé), GM-080 (Genmont), IJH-SONE68 (plant-derived), LT12, Shirota-type

Benefits

Upper respiratory symptom duration

Trilling B et al. 2015 (, Am J Clin Nutr 102:330-340) — randomized double-blind placebo-controlled trial in 1,104 healthy adults aged 18-60 at 2 centers (Germany + Denmark). ≥1×10⁹ CFU L. casei 431® daily for 42 days with day-21 influenza vaccination. Reduced duration of upper respiratory symptoms. Honest framing: NO effect on antibody response components — the respiratory symptom benefit does NOT translate to improved vaccine antibody titers. Different mechanism: mucosal immunity vs systemic antibody response.

Supported by Trial 1

Pollen allergy (KW3110, Kirin)

L. paracasei KW3110 — 14 pollen allergy patients on 4×10¹⁰ CFU/day yogurt for 12 weeks. Th2 cell generation repressed; eosinophil activation repressed. Small sample size for the pollen-allergy indication; suggests Th1/Th2 immune balance shift toward Th1 dominance.

Supported by Trial 3

Pediatric allergic rhinitis (GM-080)

— 122 pediatric perennial allergic rhinitis patients on 2×10⁹ CFU/day GM-080 for 3 months. Significant improvement in sneezing and Investigator Global Assessment vs placebo. Pediatric-specific evidence for the GM-080 strain.

Supported by Trial 2

Allergic rhinitis (NCC2461, Nestlé)

NCC2461 (Nestlé) — initial pilot proof of efficacy in allergic rhinitis volunteers; crossover RCT extends evidence. Distinct strain-specific evidence base — should not be assumed equivalent to other L. paracasei strains.

Supported by Trial 2, Trial 3

Chronic allergy (IJH-SONE68 plant-derived)

— 60 chronic allergy subjects, IJH-SONE68 for 12 weeks. Significant self-assessed allergic status and inflammation marker improvements. Plant-derived (pineapple juice broth fermentation) — important option for vegan or dairy-allergic populations.

Supported by Trial 3

meta-analysis of probiotics for AR (30 RCTs)

meta-analysis of 30 RCTs of probiotics for allergic rhinitis. Improved Rhinitis QoL and Total Symptom scores, but NOT immunological parameters (eosinophil count, IgE titers unchanged). Honest framing: probiotic AR benefits are symptomatic, not immunological — clinical relevance present but mechanistic understanding incomplete.

Supported by Trial 1, Trial 2

Mechanism of action

1

Th1 induction and Th2 repression

Distinguishing immunomodulation profile — shifts the balance toward Th1 (which is suppressive of allergic Th2 responses). Mechanistic basis for the allergy-specific applications across strains.

2

TLR2 and dendritic cell activation

L. paracasei strains activate TLR2 receptors on dendritic cells, modulating downstream T cell polarization. Foundational innate immune pathway.

3

Exopolysaccharide (EPS) bioactivity (IJH-SONE68)

IJH-SONE68 specifically produces an exopolysaccharide with documented bioactivity. Strain-specific structural feature that may underlie the chronic-allergy benefits beyond standard L. paracasei pathways.

4

Strain-specific bioactive profiles

L. casei 431® vs KW3110 vs NCC2461 vs GM-080 vs IJH-SONE68 each have distinct bioactive profiles. Strain-level chemistry differs; clinical evidence cannot be transferred between strains.

5

Eosinophil activation suppression

KW3110 — repressed eosinophil activation in pollen allergy patients. Mechanistic finding consistent with the Th1 shift.

6

Mucosal vs systemic immunity (vaccine response evidence)

Trilling 2015 found respiratory symptom benefit WITHOUT vaccine antibody response improvement — suggesting the strain operates at the mucosal level (reducing local respiratory pathology) rather than via systemic antibody enhancement. Different mechanism than most vaccine-adjuvant approaches.

Clinical trials

1
Trilling 2015 — L. casei 431® Influenza Vaccine 1,104-pt RCT (PIVOTAL)

Trilling B et al. 2015 (PMID 25926507, Am J Clin Nutr 102:330-340). Randomized double-blind placebo-controlled trial in 1,104 healthy adults aged 18-60 at 2 centers (Germany + Denmark). ≥1×10⁹ CFU L. casei 431® for 42 days with day-21 influenza vaccination. Reduced duration of upper respiratory symptoms; NO effect on antibody response components. Important honest finding: respiratory symptom benefit does not translate to improved vaccine antibody titers.

2
GM-080 — Pediatric Allergic Rhinitis 122-Patient 3-Month RCT (PMC10000597)

PMC10000597. 122 pediatric perennial allergic rhinitis patients on 2×10⁹ CFU/day GM-080 for 3 months. Significant improvement in sneezing and Investigator Global Assessment vs placebo.

3
PMC8623948 — IJH-SONE68 Chronic Allergy 60-Subject 12-Week RCT

PMC8623948. 60 chronic allergy subjects on IJH-SONE68 for 12 weeks. Significant self-assessed allergic status and inflammation marker improvements. Plant-derived (pineapple juice broth fermentation) — option for vegan or dairy-allergic populations.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; food-grade probiotic origin.
Mild GI upset, bloating (rare; transient).
Pregnancy/lactation: food-grade origin supports general safety; specific data limited.
Long-term safety: multiple multi-month trials supportive.
Allergic reactions in milk-derived ingredient sensitivities (rare; plant-derived IJH-SONE68 alternative).
Industry-sponsorship variable across strains — important context.
Strain identity verification important — generic 'L. paracasei' not equivalent.

Important Drug interactions

Antibiotics: take 2-3 hours apart from probiotic dose.
Most medications: well-tolerated combination profile.
Antihistamines: theoretical complementary effects in allergic rhinitis.
Vaccines: NO antibody response enhancement (Trilling 2015 negative finding) but possible respiratory symptom reduction.
Immunosuppressants: caution (applies to all probiotics).
Other probiotics: compatible.
Featured In

Symptom-specific supplement guides

🤧Best Supplements for Allergies🌿Best Supplements for Eczema

More Immune Support Ingredients

Immune Support
Vitamin C
Vitamin C, also known as ascorbic acid, is a water-soluble vitamin commonly used in supple…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…
Immune Support
Vitamin A
Vitamin A is a fat-soluble nutrient essential for vision, immune function, and cellular gr…

Explore Other Ingredients

Immune Support
Reishi Mushroom
Reishi mushroom, known as the 'mushroom of immortality' in Traditional Chinese Medicine, h…
Immune Support
Turkey Tail Mushroom
Turkey Tail is a polypore mushroom with a long history of use in Traditional Chinese Medic…
Immune Support
Probiotics (Multi-strain Blends)
Multi-strain probiotic blends are the most common form of probiotic supplements — typicall…

Frequently asked questions about Lactobacillus paracasei (Multi-Strain Specialist)

What is Lactobacillus paracasei (Multi-Strain Specialist)?

A probiotic species (recently reclassified taxonomically as Lacticaseibacillus paracasei) with multiple strain-specific clinical applications — strain selection is essential because different strains have distinct evidence bases.

What does Lactobacillus paracasei (Multi-Strain Specialist) do?

Distinguishing immunomodulation profile — shifts the balance toward Th1 (which is suppressive of allergic Th2 responses). Mechanistic basis for the allergy-specific applications across strains. In clinical research, Lactobacillus paracasei (Multi-Strain Specialist) has been studied for upper respiratory symptom duration, pollen allergy (kw3110, kirin), pediatric allergic rhinitis (gm-080).

Who should take Lactobacillus paracasei (Multi-Strain Specialist)?

Lactobacillus paracasei (Multi-Strain Specialist) may be most relevant for people interested in immune support, respiratory health, gut health. It has been clinically studied for upper respiratory symptom duration, pollen allergy (kw3110, kirin), pediatric allergic rhinitis (gm-080). As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Lactobacillus paracasei (Multi-Strain Specialist) take to work?

In clinical trials, effects typically appear over 12+ weeks of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Lactobacillus paracasei (Multi-Strain Specialist)?

For immune support, Lactobacillus paracasei (Multi-Strain Specialist) can typically be taken in the morning with breakfast. For acute illness use, follow product labeling — dosing frequency and timing may differ from preventive use. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Lactobacillus paracasei (Multi-Strain Specialist) worth taking?

Lactobacillus paracasei (Multi-Strain Specialist) has moderate clinical evidence (Evidence Level 3/5 on NutraSmarts) — meaningful trial support exists, though results are less consistent than top-tier ingredients. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Lactobacillus paracasei (Multi-Strain Specialist) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Lactobacillus paracasei (Multi-Strain Specialist)?

The clinically studied dose for Lactobacillus paracasei (Multi-Strain Specialist) is L. CASEI 431® RESPIRATORY: ≥1×10⁹ CFU/day × 42 days. KW3110 POLLEN ALLERGY: 4×10¹⁰ CFU/day yogurt × 12 weeks. GM-080 PEDIATRIC AR: 2×10⁹ CFU/day × 3 months. IJH-SONE68 CHRONIC ALLERGY: per trial × 12 weeks. Strain selection essential — generic L. paracasei not equivalent.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Lactobacillus paracasei (Multi-Strain Specialist) used for?

Lactobacillus paracasei (Multi-Strain Specialist) is studied for upper respiratory symptom duration, pollen allergy (kw3110, kirin), pediatric allergic rhinitis (gm-080). Trilling B et al. 2015 (, Am J Clin Nutr 102:330-340) — randomized double-blind placebo-controlled trial in 1,104 healthy adults aged 18-60 at 2 centers (Germany + Denmark). ≥1×10⁹ CFU L.